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A Hurdle in the Road to Personalized Antiplatelet Therapy?*Ori Ben-Yehuda, MDT he recognition that platelets play a centralrole in stent thrombosis and the develop-ment of the adenosine diphosphate receptor
(e.g., the P2Y12 receptor) antagonists have been
instrumental in making coronary stenting a corner-
stone in the treatment of ischemic heart disease.
The institution of dual-antiplatelet therapy with
aspirin and a P2Y12 inhibitor, alongwith improvements
in stent design, have reduced stent thrombosis
rates from as high as 7% to 28% in the early days of
stenting (1) to <1% with dual-antiplatelet therapy and
second-generation drug-eluting stents (2). Despite
this remarkable improvement in outcomes, stent
thrombosis remains a vexing problem due to its sud-
den onset and high mortality.
Various factors have been associated with stent
thrombosis (3), including stent characteristics (strut
thickness and design, polymer, and metal used);
comorbidities and clinical presentation (diabetes,
acute coronary syndromes [particularly ST-segment
elevation myocardial infarction]); anatomic consid-
erations (stent length, presence of complex lesions);
procedural factors (previous brachytherapy, inade-
quate stent expansion, residual edge dissection); type
and duration of antiplatelet therapy; and particularly
with the use of clopidogrel, genetic factors, such as
the presence of polymorphisms that affect the func-
tion of the CYP2C19 enzyme critical for the metab-
olism and activation of clopidogrel.
The patient’s response to P2Y12 blockade can be
assessed by testing for residual (on-treatment) high
platelet reactivity (HPR). Although not addressing all
the factors potentially putting the patient at risk of* Editorials published in the Journal of the American College of Cardiology
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contents of this paper to disclose.stent thrombosis, residual platelet reactivity can be
considered as a “holistic” test, which may reﬂect
compliance, dose, drug absorption, genetics, and
underlying inﬂammation (reviewed in Tantry et al.
[4]). Various tests including the VerifyNow P2Y12 test
(Accumetrics, San Diego, California), the Multiplate
Assay (Roche, Basel, Switzerland), the thromboelas-
tography platelet mapping assay, and the vasodilator-
stimulated phosphoprotein (VASP) platelet reactivity
index test have been studied for assessing platelet
reactivity (4). Several studies have identiﬁed HPR as
predicting stent thrombosis as well as other ischemic
events. Equally important, the ADAPT-DES (Assess-
ment of Dual AntiPlatelet Therapy with Drug-Eluting
Stents) study (5) with 8,665 patients undergoing
percutaneous coronary intervention identiﬁed HPR
(deﬁned as platelet reactivity units [PRU] >208 or
>230) as not only being associated with stent
thrombosis, but also being inversely associated with
bleeding, thereby highlighting the balance between
antithrombotic effect and bleeding.
Identifying HPR, although providing prognostic
information, would be of critical importance if it also
led to interventions that reduced the risk of stent
thrombosis. In this regard, the evidence has been
mixed. The GRAVITAS (Gauging Responsiveness with
A VerifyNow assay-Impact on Thrombosis and Safety)
trial (6) randomized 2,214 patients with HPR to
standard-dose or high-dose clopidogrel. Although
the high-dose regimen resulted in an absolute 22%
reduction in the rate of HPR at 30 days, the primary
endpoint of cardiovascular death, nonfatal myocardial
infarction, or stent thrombosis at 6 months was iden-
tical at 2.3% in both groups. Two additional studies,
TRIGGER-PCI (Testing Platelet Reactivity in Patients
Undergoing Elective Stent Placement on Clopidogrel
to Guide Alternative Therapy With Prasugrel) (7)
and ARCTIC (Assessment by a Double Randomization
of a Conventional Antiplatelet Strategy versus a
Monitoring-guided Strategy for Drug-Eluting Stent
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370Implantation and of Treatment Interruption versus
Continuation One Year After Stenting) (8), also did not
prove the beneﬁt of platelet function testing–guided
therapy. Conversely, a number of smaller studies
including a recently reported trial by Aradi et al. (9)
reported positive results, and a meta-analysis of 9
studies concluded that intensiﬁed therapy in patients
with HPR reduced cardiovascular mortality and stent
thrombosis (10).
An underlying assumption of platelet reactivity
testing is that the results of such testing performed in
the immediate post-stenting period would be some-
what stable over time. Surprisingly, few data have
been available until now concerning this important
aspect (i.e., the potential chronovariability of on-
treatment platelet reactivity). Previous studies ad-
dressing this issue were either small (11) or did not
focus on the individual change in platelet reactivity,
rather focusing on the overall ﬁndings in a given
population. In this issue of the Journal, Hochholzer
et al. (12) report on the time variability of platelet
response to clopidogrel using data from the ELEVATE–
TIMI 56 (Escalating Clopidogrel by Involving a Genetic
Strategy–Thrombolysis In Myocardial Infarction 56)SEE PAGE 361trial (13). ELEVATE–TIMI 56 was a trial assessing the
relationship between different maintenance doses of
clopidogrel and CYP2C19 genotype and platelet
reactivity. Serial platelet function testing was carried
out using the VerifyNow assay, as well as a VASP
assay. Only subjects without the CYP2C19*2 loss of
function polymorphism were included in the present
analysis as two assays were available at 2 different
time points on the same dose of clopidogrel in this
subgroup. In total, data were available for 210 pa-
tients on 75 mg of clopidogrel daily and 209 patients
on 150 mg of clopidogrel daily. Although the total
proportion of patients with HPR did not change be-
tween periods, a signiﬁcant number of individual pa-
tients (15.7%) changed from HPR to non-HPR status
and vice versa using a cutoff of PRU of 230. Similar
ﬁndings were conﬁrmed using a cutoff of 208 for PRU,
as well as when platelet reactivity was assessed as a
continuous variable. As many as 40% had a change of
at least 40 PRU over time. Similar ﬁndings were foundusing the VASP test. The clinical variables most asso-
ciated with a change in platelet function were the
presence of diabetes mellitus and body mass index.
The ﬁndings from the study by Hochholzer et al.
(13) highlight that even in a population with stable
coronary disease, platelet reactivity while on clopi-
dogrel, whether high or low, may not be stable. The
strengths of the study include the rigorous assess-
ment of platelet function and control for comorbid-
ities. There are, however, also some limitations
including the short time period (14 days) between
the platelet function assessments and the weak
correlations between the VASP and VerifyNow tests.
What are the implications of these ﬁndings? Do
they explain the negative results of studies, such as
the GRAVITAS trial as suggested by the authors? If
the chronovariability of HPR negated the effects of
baseline platelet function assays, then one would
not expect large observational studies, such as the
ADAPT-DES, to show a signiﬁcant predictive effect of
HPR. The most likely explanation for the failure of
most (but not all) studies using baseline platelet
reactivity assays remains the low event rate in those
studies, as well as the modest incremental platelet
inhibition achieved with increased clopidogrel
doses. Indeed, other studies that have used prasu-
grel in patients with HPR did demonstrate a reduc-
tion in events (9). Yet any variability over time
would be expected to reduce the power as well as
actual clinical efﬁcacy of any intervention trial,
particularly given the balance between thrombotic
and bleeding events.
Testing for HPR was expected to provide guidance
that would allow personalizing antiplatelet therapy.
The ﬁndings reported by Hochholzer et al. (12) pro-
vide an important caution in categorizing individual
patients in terms of their platelet reactivity. Further
studies on HPR, whether observational or with a
planned intervention (such as switching from clopi-
dogrel to prasugrel or ticlopidine), should monitor
platelet reactivity over time.
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